VRTX · News · 20260826N

KALYDECO Generic Competition

VERTEX PHARMACEUTICALS INC / MA · 2026-08-26 · Importance 40 · Surprise 42 · In source text

A U.S. federal judge ruled that Lupin Ltd.'s proposed generic versions of Vertex's cystic-fibrosis drug KALYDECO do not infringe four Vertex patents. The dispute focused on the interpretation of the patented ivacaftor concentration of “about 80%.” The ruling prevents Vertex from blocking Lupin's generic versions by asserting a broader scope for its patent claims, creating potential future competition for KALYDECO in the U.S. market.

Key facts

• A federal judge ruled that Lupin Ltd.'s proposed generic versions of Vertex Pharmaceuticals Inc.'s cystic fibrosis drug Kalydeco do not infringe on four of Vertex's patents. source
• The decision prevents Vertex from blocking Lupin's generic versions by expanding the scope of its patent claims. source
• A US court rejected Vertex's patent claims for a key cystic fibrosis drug. source
• The ruling centered on the interpretation of "about 80%" concentration of the active ingredient ivacaftor. source
• The judge concluded that Vertex was attempting to claim a wider range than originally patented. source

Impact estimates